Cell-cycle control in urothelial carcinoma: Large-scale tissue array analysis of tumor tissue from Maine and Vermont

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 9, 2012, Pages 1555-1564

  Lenz, Petra ^a   Pfeiffer, Ruth ^b   Baris, Dalsu ^b   Schned, Alan R ^c   Takikita, Mikiko ^b   Poscablo, M Cristina ^b   Schwenn, Molly ^d   Johnson, Alison ^e   Jones, Michael ^f   Kida, Masatoshi ^g   Cantor, Kenneth P ^h   Rothman, Nathaniel ^b   Silverman, Debra T ^b   Hewitt, Stephen M ^c   Moore, Lee E ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d Maine Cancer Registry   (United States)

^e Vermont Cancer Registry   (United States)

^f MAINE MEDICAL CENTER   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^h KP Cantor Environmental LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; PROTEIN P63; RETINOBLASTOMA PROTEIN;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CASE CONTROL STUDY; CELL CYCLE REGULATION; CIGARETTE SMOKING; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SCORING SYSTEM; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UNITED STATES;

ADULT; AGED; CELL CYCLE; CYCLIN D1; FEMALE; HUMANS; KI-67 ANTIGEN; MAINE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; VERMONT;

EID: 84866145906     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0261     Document Type: Article

References (33)

1. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992;6:1-30.
2. Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170:438-41.
3. Zhang ZF, Cordon-Cardo C, Rothman N, Freedman AN, Taylor JA. Methodological issues in the use of tumour markers in cancer epidemiology. IARC Sci Publ 1997;201-13.
4. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;119:1513-8.
5. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 2008;154-65.
6. Baffa R, Letko J, McClung C, LeNoir J, Vecchione A, Gomella LG. Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res 2006;25:145-60.
7. Grossfeld GD, Muscheck M, Stein JP, Chew K, Cote RJ, Ginsberg DA, et al. Cellular proliferation and cell-cell cycle regulatory proteins as prognostic markers for transitional cell carcinoma of the bladder. Adv Exp Med Biol 1999;462:425-35.
8. Luis NM, Lopez-Knowles E, Real FX. Molecular biology of bladder cancer. Clin Transl Oncol 2007;9:5-12.
9. Kelsey KT, Hirao T, Hirao S, Devi-Ashok T, Nelson HH, Andrew A, et al. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. Int J Cancer 2005;117:370-5.
10. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002;161:1199-206.
11. Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer 2004;100:2367-75.
12. Quentin T, Henke C, Korabiowska M, Schlott T, Zimmerman B, Kunze E. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 2004;24:1011-23.
13. Brunner A, Verdorfer I, Prelog M, Mayerl C, Mikuz G, Tzankov A. Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers. Pathobiology 2008;75:25-33.
14. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-64.
15. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 2007;25:468-75.
16. Mulder AH, Van Hootegem JC, Sylvester R, ten Kate FJ, Kurth KH, Ooms EC, et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol 1992;166:37-43.
17. Rossman TG. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 2003;533:37-65.
18. Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, et al. A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst 2009;101:1553-61.
19. Kelsey KT, Hirao T, Schned A, Hirao S, Devi-Ashok T, Nelson HH, et al. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 2004;90:1572-6.
20. Moore LE, Smith AH, Eng C, DeVries S, Kalman D, Bhargava V, et al. P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis 2003;24:1785-91.
21. Yeniyol CO, Suelozgen T, Vardar E, Sural S, Postaci H, Ayder AR. The relation of mutant p53 accumulation in transitional cell carcinoma of bladder with pathological stage, grade, recurrence and survival. Int Urol Nephrol 2001;33:473-8.
22. Toktas G, Turkeri LN, Unluer E, Caliskan M, Aksoy B, Akdas A. Clinical significance of nuclear p53 protein accumulation in bladder cancer. Int Urol Nephrol 1999;31:327-34.
23. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev 2009;28:269-80.
24. Comperat E, Bieche I, Dargere D, Ferlicot S, Laurendeau I, Benoit G, et al. p63 gene expression study and early bladder carcinogenesis. Urology 2007;70:459-62.
25. Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 2004;63:1079-83.
26. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003;9:5501-7.
27. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 2003;28:663-70.
28. Takagi Y, Takashi M, Koshikawa T, Sakata T, Ohshima S. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 2000;7:366-72.
29. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37:1568-76.
30. Bol MG, Baak JP, van Diermen B, Buhr-Wildhagen S, Janssen EA, Kjellevold KH, et al. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. J Clin Pathol 2003;56:447-52.
31. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009;101:114-9.
32. Zhang ZF, Sarkis AS, Cordon-Cardo C, Dalbagni G, Melamed J, Aprikian A, et al. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 1994;3:19-24.
33. Curigliano G, Zhang YJ, Wang LY, Flamini G, Alcini A, Ratto C, et al. Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis 1996;17:911-6.